These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 29061350

  • 1. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.
    Ly HJ, Nishiyama S, Lokugamage N, Smith JK, Zhang L, Perez D, Juelich TL, Freiberg AN, Ikegami T.
    Vaccine; 2017 Dec 04; 35(48 Pt B):6634-6642. PubMed ID: 29061350
    [Abstract] [Full Text] [Related]

  • 2. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.
    Ikegami T, Hill TE, Smith JK, Zhang L, Juelich TL, Gong B, Slack OA, Ly HJ, Lokugamage N, Freiberg AN.
    J Virol; 2015 Jul 04; 89(14):7262-76. PubMed ID: 25948740
    [Abstract] [Full Text] [Related]

  • 3. Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.
    Ly HJ, Lokugamage N, Nishiyama S, Ikegami T.
    PLoS One; 2017 Jul 04; 12(9):e0185194. PubMed ID: 28926632
    [Abstract] [Full Text] [Related]

  • 4. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.
    Ikegami T.
    Expert Rev Vaccines; 2017 Jun 04; 16(6):601-611. PubMed ID: 28425834
    [Abstract] [Full Text] [Related]

  • 5. Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.
    Nishiyama S, Slack OA, Lokugamage N, Hill TE, Juelich TL, Zhang L, Smith JK, Perez D, Gong B, Freiberg AN, Ikegami T.
    Virulence; 2016 Nov 16; 7(8):871-881. PubMed ID: 27248570
    [Abstract] [Full Text] [Related]

  • 6. Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves.
    Boumart Z, Daouam S, Bamouh Z, Jazouli M, Tadlaoui KO, Dungu B, Bettinger G, Watts DM, Elharrak M.
    Vaccine; 2019 Mar 14; 37(12):1642-1650. PubMed ID: 30773401
    [Abstract] [Full Text] [Related]

  • 7. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.
    Indran SV, Lihoradova OA, Phoenix I, Lokugamage N, Kalveram B, Head JA, Tigabu B, Smith JK, Zhang L, Juelich TL, Gong B, Freiberg AN, Ikegami T.
    J Gen Virol; 2013 Jul 14; 94(Pt 7):1441-1450. PubMed ID: 23515022
    [Abstract] [Full Text] [Related]

  • 8. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates.
    Smith DR, Johnston SC, Piper A, Botto M, Donnelly G, Shamblin J, Albariño CG, Hensley LE, Schmaljohn C, Nichol ST, Bird BH.
    PLoS Negl Trop Dis; 2018 May 14; 12(5):e0006474. PubMed ID: 29742102
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome.
    Ayers VB, Huang YS, Dunlop JI, Kohl A, Brennan B, Higgs S, Vanlandingham DL.
    Viral Immunol; 2023 Jan 14; 36(1):33-40. PubMed ID: 36399689
    [Abstract] [Full Text] [Related]

  • 10. The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.
    Nishiyama S, Lokugamage N, Ikegami T.
    J Virol; 2016 Jan 27; 90(7):3735-44. PubMed ID: 26819307
    [Abstract] [Full Text] [Related]

  • 11. Distinct Pathological Changes in Preweaning Mice Infected with Live-Attenuated Rift Valley Fever Virus Strains.
    Alkan C, Jurado-Cobena E, Ikegami T.
    Viruses; 2024 Jun 21; 16(7):. PubMed ID: 39066162
    [Abstract] [Full Text] [Related]

  • 12. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.
    Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B, McElroy AK, Khristova ML, Albariño CG, Nichol ST.
    J Virol; 2011 Dec 21; 85(24):12901-9. PubMed ID: 21976656
    [Abstract] [Full Text] [Related]

  • 13. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge.
    Gowen BB, Bailey KW, Scharton D, Vest Z, Westover JB, Skirpstunas R, Ikegami T.
    Antiviral Res; 2013 May 21; 98(2):135-43. PubMed ID: 23523764
    [Abstract] [Full Text] [Related]

  • 14. A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice.
    Terasaki K, Juelich TL, Smith JK, Kalveram B, Perez DD, Freiberg AN, Makino S.
    Sci Rep; 2018 Nov 20; 8(1):17097. PubMed ID: 30459418
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania.
    Nyundo S, Adamson E, Rowland J, Palermo PM, Matiko M, Bettinger GE, Wambura P, Morrill JC, Watts DM.
    Onderstepoort J Vet Res; 2019 Jan 31; 86(1):e1-e8. PubMed ID: 30843406
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep.
    Weingartl HM, Nfon CK, Zhang S, Marszal P, Wilson WC, Morrill JC, Bettinger GE, Peters CJ.
    Vaccine; 2014 Apr 25; 32(20):2345-9. PubMed ID: 24462482
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.
    Warimwe GM, Lorenzo G, Lopez-Gil E, Reyes-Sandoval A, Cottingham MG, Spencer AJ, Collins KA, Dicks MD, Milicic A, Lall A, Furze J, Turner AV, Hill AV, Brun A, Gilbert SC.
    Virol J; 2013 Dec 05; 10():349. PubMed ID: 24304565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.